Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K
Introduction to Hemostasis01:05

Introduction to Hemostasis

14.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
14.3K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
Coagulation01:09

Coagulation

8.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
8.5K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.0K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

6.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intravascular Hemolysis and Pulsed-Field Ablation: State of the Art Review.

JACC. Clinical electrophysiology·2026
Same author

Concordance Between Fragment Analysis and Next-Generation Sequencing in Identification of Non-Standard CALR Indels.

International journal of laboratory hematology·2026
Same author

Differences in intravascular hemolysis between 2 technologies for pulse field ablation of atrial fibrillation.

Heart rhythm·2025
Same author

Targeting Hsp70 Immunosuppressive Signaling Axis with Lipid Nanovesicles: A Novel Approach to Treat Pancreatic Cancer.

Cancers·2025
Same author

Endothelial ENaC-α Restrains Oxidative Stress in Lung Capillaries in Murine Pneumococcal Pneumonia-associated Acute Lung Injury.

American journal of respiratory cell and molecular biology·2024
Same author

Haemolysis index conundrum in a COVID-19 patient.

Journal of clinical pathology·2024

Related Experiment Video

Updated: May 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K

Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein.

Vladimir Y Bogdanov1, Viji Balasubramanian, James Hathcock

  • 1Division of Thrombosis Research, Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA.

Nature Medicine
|March 26, 2003
PubMed
Summary

Researchers discovered a new form of soluble tissue factor (TF) called alternatively spliced human TF (asHTF). This circulating molecule promotes blood clot formation and growth, offering new insights into thrombosis.

More Related Videos

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.4K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

1.8K

Related Experiment Videos

Last Updated: May 5, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.9K
Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis
03:53

Author Spotlight: High-Sensitivity Tissue Factor Activity Assay for Plasma Diagnosis

Published on: December 29, 2023

1.4K
Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets
10:08

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

1.8K

Area of Science:

  • Biochemistry
  • Hematology
  • Molecular Biology

Background:

  • Tissue factor (TF) initiates blood coagulation by forming a complex with FVII(a), activating FIX and FX, leading to thrombin generation.
  • TF is typically found in blood vessel walls and atherosclerotic plaques, contributing to thrombosis upon plaque rupture.
  • The circulating form and mechanism of TF in pro-thrombotic states remain incompletely understood, with potential involvement of microparticles.

Purpose of the Study:

  • To identify and characterize novel forms of human tissue factor involved in coagulation.
  • To investigate the properties and pro-coagulant activity of alternatively spliced human tissue factor (asHTF).

Main Methods:

  • Alternative splicing analysis to identify novel TF variants.
  • Biochemical assays to determine the pro-coagulant activity of asHTF.
  • In vitro studies to assess asHTF's interaction with phospholipids and thrombi.

Main Results:

  • Identification of alternatively spliced human tissue factor (asHTF), a soluble form lacking a transmembrane domain.
  • asHTF circulates in the blood and exhibits pro-coagulant activity in the presence of phospholipids.
  • asHTF incorporates into thrombi, suggesting a role in thrombus propagation.

Conclusions:

  • Alternatively spliced human tissue factor (asHTF) is a soluble, pro-coagulant molecule circulating in the blood.
  • asHTF may contribute to thrombus growth by facilitating coagulation initiation and propagation at the clot edge.
  • This discovery provides new understanding of TF's role in thrombosis and potential therapeutic targets.